Last edition
News about "RetenEx technology"
Akums Launches Enhanced Gabapentin ER Formulation for PHN
Akums Drugs and Pharmaceutical has introduced an enhanced Gabapentin Extended-Release (ER) formulation powered by its RetenEx technology for the management of postherpetic neuralgia (PHN), a chronic neuropathic pain condition that affects around 10-20 percent of patients following a shingles outbreak.
RetenEx Technology | 15/12/2025 | By News Bureau | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members